The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Discovery of OSI-906: A Selective and Orally Efficacious Dual Inhibitor of the IGF-1 Receptor and Insulin Receptor
Open accessAbstract
BACKGROUND: The IGF-1 receptor (IGF-1R) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies. Therefore, this receptor has become a major focus for the development of anticancer agents. RESULTS: Our lead optimization efforts that blended structure-based design and empirical medicinal chemistry led to the discovery of OSI-906, a novel small-molecule dual IGF-1R/insulin receptor (IR) kinase inhibitor. OSI-906 potently and selectively inhibits autophosphorylation of both human IGF-1R and IR, displays in vitro antiproliferative effects in a variety of tumor cell lines and shows robust in vivo anti-tumor efficacy in an IGF-1R-driven xenograft model when administered orally once daily. CONCLUSION: OSI-906 is a novel, potent, selective and orally bioavailable dual IGF-1R/IR kinase inhibitor with favorable preclinical drug-like properties, which has demonstrated in vivo efficacy in tumor models and is currently in clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Guide for the care and use of laboratory animals
(1997) · Choice Reviews Online · doi:10.5860/choice.34-3310 · Cited by 2,922
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Institute of Laboratory Animal Resources.
Wolfle, T. L. (1995) · Cited by 620
Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 509
The Type 1 Insulin-Like Growth Factor Receptor Pathway
Chitnis, M. M., Yuen, J. S. P., Protheroe, A. S., Pollak, M., & Macaulay, V. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4879 · Cited by 445
Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A., Kaplan, L., Burgaud, J., Carter, D., Baserga, R., et al. (1997) · PubMed · Cited by 342
Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.
Rane, A., Wilkinson, G. R., & Shand, D. G. (1977) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30786-x · Cited by 328
Jones, H. E., Goddard, L., Gee, J. M. W., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J. M., Williams, S., Wakeling, A. E., & Nicholson, R. I. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00799 · Cited by 297
Sciacca, L., Costantino, A., Pandini, G., Mineo, R., Frasca, F., Scalia, P., Sbraccia, P., Goldfine, I. D., Vigneri, R., & Belfiore, A. (1999) · Oncogene · doi:10.1038/sj.onc.1202600 · Cited by 288
Ji, Q.-S., Winnier, G. E., Niswender, K. D., Horstman, D., Wisdom, R., Magnuson, M. A., & Carpenter, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.2999 · Cited by 269
Self-citationRole of insulin-like growth factor 1 receptor signalling in cancer
Larsson, O., Girnita, A., & Girnita, L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602627 · Cited by 246
Vella, V. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.245 · Cited by 239
Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-22-cor1 · Cited by 230
Insulin receptor expression by human prostate cancers
Cox, M. E., Gleave, M. E., Zakikhani, M., Bell, R. H., Piura, E., Vickers, E., Cunningham, M., Larsson, O., Fazli, L., & Pollak, M. (2009) · The Prostate · doi:10.1002/pros.20852 · Cited by 223
Lu, Y., Zi, X., & Pollak, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 208
Insulin receptor expression and function in human breast cancer cell lines.
Milazzo, G., Giorgino, F., Damante, G., Sung, C., Stampfer, M. R., Vigneri, R., Goldfine, I. D., & Belfiore, A. (1992) · PubMed · Cited by 206
Gooch, J. L., Van Den Berg, C. L., & Yee, D. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006208721167 · Cited by 191
Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W., & Nicholson, R. I. (2005) · Endocrinology · doi:10.1210/en.2005-0247 · Cited by 188
Wang, Y., Hailey, J., Williams, D., Wang, Y., Lipari, P., Malkowski, M., Wang, X., Xie, L., Li, G., Saha, D., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0048 · Cited by 171
Eckstein, N., Servan, K., Hildebrandt, B., Pölitz, A., Jonquières, G. V., Wolf-Kümmeth, S., Napierski, I., Hamacher, A., Kassack, M. U., Budczies, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3153 · Cited by 166
The insulin-like growth factor 1 receptor in cancer: Old focus, new future
Hartog, H., Wesseling, J., Boezen, H. M., & van der Graaf, W. T. A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.021 · Cited by 163
Rodon, J., DeSantos, V., Ferry, R. J., & Kurzrock, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0265 · Cited by 162
Sciacca, L., Mineo, R., Pandini, G., Murabito, A., Vigneri, R., & Belfiore, A. (2002) · Oncogene · doi:10.1038/sj.onc.1206058 · Cited by 162
Ji, Q., Mulvihill, M. J., Rosenfeld-Franklin, M., Cooke, A. R., Feng, L., Mak, G., O’Connor, M., Yao, Y., Pirritt, C., Buck, E. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0070 · Cited by 152
Self-citationFulzele, K. S., DiGirolamo, D. J., Liu, Z., Xu, J. H., Messina, J. L., & Clemens, T. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700651200 · Cited by 149
Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer
Barnes, C. J., Ohshiro, K., Rayala, S. K., El‐Naggar, A. K., & Kumar, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2040 · Cited by 143
Entingh, A. J., & Kahn, C. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313201200 · Cited by 142
Hewish, M., Chau, I., & Cunningham, D. (2008) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489209787002515 · Cited by 141
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer
Hofmann, F., & Garcı́a-Echeverrı́a, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03512-9 · Cited by 136
Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer
Miller, B. S., & Yee, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2752 · Cited by 107
Jerome, L., Alami, N., Belanger, S., Pagé, V., Yu, Q., Paterson, J., Shiry, L., Pegram, M. D., & Leyland-Jones, B. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3555 · Cited by 106
Avnet, S., Sciacca, L., Salerno, M., Gancitano, G., Cassarino, M. F., Longhi, A., Zakikhani, M., Carboni, J. M., Gottardis, M. M., Giunti, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2645 · Cited by 103
Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation
Allen, G. W., Saba, C., Armstrong, E. A., Huang, S., Benavente, S., Ludwig, D. L., Hicklin, D. J., & Harari, P. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2000 · Cited by 94
Garton, A. J., Crew, A. P. A., Franklin, M. R., Cooke, A. R., Wynne, G. M., Castaldo, L., Kahler, J., Winski, S. L., Franks, A., Brown, E. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2873 · Cited by 85
Self-citationSmall‐molecule inhibition and activation‐loop trans‐phosphorylation of the IGF1 receptor
Wu, J., Li, W., Craddock, B. P., Foreman, K. W., Mulvihill, M. J., Ji, Q., Miller, W. T., & Hubbard, S. R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.116 · Cited by 82
Self-citationMulvihill, M. J., Ji, Q., Coate, H. R., Cooke, A. R., Dong, H., Feng, L., Foreman, K. W., Rosenfeld-Franklin, M., Honda, A., Mak, G., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.061 · Cited by 76
Self-citationPandini, G., Wurch, T., Akla, B., Corvaı̈a, N., Belfiore, A., & Goetsch, L. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.009 · Cited by 76
The therapeutic potential of agents targeting the type I insulin-like growth factor receptor
Zhang, H., & Yee, D. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.12.1569 · Cited by 75
The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma
Rose, P. P., Carroll, J. M., Carroll, P. A., DeFilippis, V. R., Lagunoff, M., Moses, A. V., Roberts, C. T., & Früh, K. (2006) · Oncogene · doi:10.1038/sj.onc.1210006 · Cited by 35
Schillaci, R., Galeano, A. C., Becú‐Villalobos, D., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05579.x · Cited by 34
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
Mitsiades, C. S., & Mitsiades, N. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.3.487 · Cited by 34
Monoclonal antibodies against components of the IGF system for cancer treatment.
Feng, Y., & Dimitrov, D. S. (2008) · PubMed · Cited by 27
Cited by
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Huang, Y.-H., Klingbeil, O., He, X.-Y., Wu, X. S., Arun, G., Lu, B., Somerville, T. D. D., Milazzo, J. P., Wilkinson, J. E., Demerdash, O. E., et al. (2018) · Genes & Development · doi:10.1101/gad.314815.118 · Cited by 422
Marcel, V., Ghayad, S. E., Belin, S., Therizols, G., Morel, A.-P., Solano-Gonzàlez, E., Vendrell, J. A., Hacot, S., Mertani, H. C., Albaret, M. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.013 · Cited by 358
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., Florin, A., Ozretić, L., Lim, D., Wang, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3667 · Cited by 268
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Beekhof, R., van Alphen, C., Henneman, A. A., Knol, J. C., Pham, T. V., Rolfs, F., Labots, M., Henneberry, E., Le Large, T. Y., de Haas, R. R., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188250 · Cited by 97
Metadata
- Authors
- Mulvihill, M. J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K., Landfair, D., O’Connor, M., Pirritt, C., Sun, Y., Yao, Y., Arnold, L. D., Gibson, N. W., & Ji, Q.-S.
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 1
- Issue
- 6
- Pages
- 1153-1171
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2141398932
- Cited by
- 311
- References
- 47
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.